1.29

0.78% 0.01

After Hours: 1.23 -0.06 -4.65%

Plus Therapeutics Inc (PSTV)

Overview News Price History Financials Discussions Forecast Stock Split

Plus Therapeutics Inc stock is traded at $1.29, with a volume of 30,364. It is up +0.78% in the last 24 hours and down -4.44% over the past month. Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Previous Close:

$1.28

Open:

$1.3

24h Volume:

30,364

Relative Volume:

0.38

Market Cap:

$7.55M

Revenue:

Net Income/Loss:

$-13.32M

P/E Ratio:

-0.2143

EPS:

-6.02

Net Cash Flow:

$-13.01M

1W Performance:

+4.88%

1M Performance:

-4.44%

6M Performance:

-41.63%

1Y Performance:

-28.33%

1-Day Range:

$1.2441

$1.3184

1-Week Range:

$1.23

$1.3292

52-Week Range:

$1.12

$2.6702

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name

Plus Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (683)

Phone

737.255.7194

Address

4200 MARATHON BLVD., AUSTIN, TX

Employee

Twitter

@plustxinc

Next Earnings Date

2024-11-04

Latest SEC Filings

PSTV's Discussions on Twitter

Compare PSTV with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PSTV Plus Therapeutics Inc	1.29	7.55M	0	-13.32M	-13.01M	-4.39
VRTX Vertex Pharmaceuticals Inc	465.73	119.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	762.34	82.77B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	617.49	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.01	32.63B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.20	28.10B	3.30B	-501.07M	1.03B	-2.1146

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-25-21	Initiated	Ladenburg Thalmann	Buy
Oct-16-20	Initiated	Maxim Group	Buy

Plus Therapeutics Inc Stock (PSTV) Latest News

Nov 30, 2024

HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World

Nov 30, 2024

Nov 26, 2024

Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com

Nov 26, 2024

Nov 25, 2024

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network

Nov 25, 2024

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire

Nov 25, 2024

Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan

Nov 25, 2024

Nov 22, 2024

PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan

Nov 22, 2024

PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK

Nov 22, 2024

Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire

Nov 22, 2024

Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan

Nov 22, 2024

Nov 21, 2024

Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire

Nov 21, 2024

Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan

Nov 21, 2024

Nov 19, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World

Nov 19, 2024

Nov 18, 2024

Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com

Nov 18, 2024

Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com

Nov 18, 2024

Nov 17, 2024

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Plus: Q3 Earnings Snapshot - New Haven Register

Nov 15, 2024